• Something wrong with this record ?

Targeting APRIL in the treatment of glomerular diseases

CK. Cheung, J. Barratt, R. Lafayette, A. Liew, Y. Suzuki, V. Tesař, H. Trimarchi, MG. Wong, H. Zhang, DV. Rizk

. 2024 ; 106 (5) : 806-818. [pub] 20240907

Language English Country United States

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc25003691

A proliferation-inducing ligand (APRIL) is a key member of the tumor necrosis factor superfamily of cytokines and plays a central role in B-cell survival, proliferation, and Ig class switching. Recently, there has been increasing interest in the role of APRIL and the related cytokine B-cell activating factor in several glomerular diseases, because of their importance in the above processes. The therapeutic inhibition of APRIL represents a potentially attractive immunomodulatory approach that may abrogate deleterious host immune responses in autoimmune diseases while leaving other important functions of humoral immunity intact, such as memory B-cell function and responses to vaccination, in contrast to B-cell-depleting strategies. In this review, we describe the physiological roles of APRIL in B-cell development and their relevance to glomerular diseases, and outline emerging clinical trial data studying APRIL inhibition, with a focus on IgA nephropathy where the clinical development of APRIL inhibitors is in its most advanced stage.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003691
003      
CZ-PrNML
005      
20250206104621.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.kint.2024.08.012 $2 doi
035    __
$a (PubMed)39182759
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Cheung, Chee Kay $u Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; John Walls Renal Unit, University Hospitals of Leicester National Health Service Trust, Leicester, UK
245    10
$a Targeting APRIL in the treatment of glomerular diseases / $c CK. Cheung, J. Barratt, R. Lafayette, A. Liew, Y. Suzuki, V. Tesař, H. Trimarchi, MG. Wong, H. Zhang, DV. Rizk
520    9_
$a A proliferation-inducing ligand (APRIL) is a key member of the tumor necrosis factor superfamily of cytokines and plays a central role in B-cell survival, proliferation, and Ig class switching. Recently, there has been increasing interest in the role of APRIL and the related cytokine B-cell activating factor in several glomerular diseases, because of their importance in the above processes. The therapeutic inhibition of APRIL represents a potentially attractive immunomodulatory approach that may abrogate deleterious host immune responses in autoimmune diseases while leaving other important functions of humoral immunity intact, such as memory B-cell function and responses to vaccination, in contrast to B-cell-depleting strategies. In this review, we describe the physiological roles of APRIL in B-cell development and their relevance to glomerular diseases, and outline emerging clinical trial data studying APRIL inhibition, with a focus on IgA nephropathy where the clinical development of APRIL inhibitors is in its most advanced stage.
650    _2
$a lidé $7 D006801
650    12
$a protein TALL-2 $x antagonisté a inhibitory $x imunologie $7 D053300
650    12
$a B-lymfocyty $x imunologie $x účinky léků $7 D001402
650    12
$a IgA nefropatie $x imunologie $x farmakoterapie $7 D005922
650    _2
$a zvířata $7 D000818
650    _2
$a glomerulus $x imunologie $x patologie $x účinky léků $7 D007678
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Barratt, Jonathan $u Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; John Walls Renal Unit, University Hospitals of Leicester National Health Service Trust, Leicester, UK
700    1_
$a Lafayette, Richard $u Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford University, Stanford, California, USA
700    1_
$a Liew, Adrian $u The Kidney and Transplant Practice, Mount Elizabeth Novena Hospital, Singapore
700    1_
$a Suzuki, Yusuke $u Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan
700    1_
$a Tesař, Vladimír $u Department of Nephrology, General University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Trimarchi, Hernán $u Nephrology Service and Kidney Transplant Unit, Hospital Británico de Buenos Aires, Buenos Aires, Argentina
700    1_
$a Wong, Muh Geot $u Department of Renal Medicine, Concord Repatriation General Hospital, Concord, Australia; Department of Medicine, University of Sydney, Camperdown, Australia
700    1_
$a Zhang, Hong $u Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, People's Republic of China
700    1_
$a Rizk, Dana V $u Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Electronic address: drizk@uabmc.edu
773    0_
$w MED00010141 $t Kidney international $x 1523-1755 $g Roč. 106, č. 5 (2024), s. 806-818
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39182759 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104616 $b ABA008
999    __
$a ok $b bmc $g 2263447 $s 1239698
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 106 $c 5 $d 806-818 $e 20240907 $i 1523-1755 $m Kidney international $n Kidney Int $x MED00010141
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options